Feedback
Bullous Pemphigoid Antigens (180 kDa and 230 kDa), IgG
0092566
Ordering Recommendation
•Monitor disease in patient previously diagnosed with pemphigoid and increased antibodies for IgG BP180 and/or BP230; IgG BP180 antibody levels correlate with disease activity.
•For initial diagnosis and assessment of disease progression or changes, the preferred test is the pemphigoid antibody panel (0092001); panel components include IgG and IgA epithelial BMZ antibodies and IgG bullous pemphigoid (BP 180 and 230) antigens.
•To determine the involvement of IgG BMZ antibodies and pattern of reactivity on split skin substrate, order with antibody testing for IgG epithelial BMZ  (0092056).
•Also, consider other types of BMZ antibody-associated disease testing, (i.e., IgA epithelial BMZ (0092057), IgG collagen type VII (2010905), or herpes gestationis factor (0092283)).
Mnemonic
BP180 230G
Methodology
Enzyme-Linked Immunosorbent Assay
Performed
Varies
Reported
3-11 days  
New York DOH Approval Status
This test is New York DOH approved.
Specimen Required
Patient Preparation
  
Collect
Plain red or serum separator tube (SST).  
Specimen Preparation
Transfer 2 mL serum to an ARUP Standard Transport Tube. (Min: 0.5 mL)  
Storage/Transport Temperature
Refrigerated.  
Unacceptable Conditions
Hemolyzed or lipemic specimens.  
Remarks
  
Stability
Ambient: 1 week; Refrigerated: 2 weeks; Frozen: Indefinitely  
Reference Interval
By report  
Interpretive Data
 
Note
For specimens less than 0.5 mL, call the Immunodermatology Laboratory at (866) 266-5699.
CPT Code(s)
83516 x2
Components
Component Test Code*Component Chart NameLOINC
0092568Bullous Pemphigoid Antigens, IgG57911-0
2010915EER Bullous Pemphigoid Antigens, IgG 
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Aliases
  • BP 180 and BP 230
  • BP Antigen 1
  • BP Antigen 2

Performed at UUHC-Immunodermatology